RNAZ

RNAZ

USD

TransCode Therapeutics Inc. Common Stock

$9.500-0.410 (-4.137%)

Reaalajas hind

Healthcare
Biotehnoloogia
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$9.910

Kõrge

$10.450

Madal

$9.500

Maht

0.01M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

8.7M

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

0.14M

Börs

NCM

Valuuta

USD

52 nädala vahemik

Madal $6.15Praegune $9.500Kõrge $494.34

Seotud uudised

PR Newswire

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announces completion of Phase 1a clinical trial with TTX-MC138, an investigational inhibitor of...

Vaata rohkem
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
PR Newswire

TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) ("TransCode or the "Company") announced today that it entered into a definitive agreement to acquire...

Vaata rohkem
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.